The safety of mRNA vaccines, hailed as a saviour in the covid-19 pandemic, has been called into question by the US ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

The U.S. is facing its worst flu season in 25 years, according to the Centers for Disease Control and Prevention, which ...

US drugmaker Moderna heads into 2026 with stronger finances and a crowded late-stage pipeline after an aggressive cost reset ...

Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...

An analysis of more than one million people in the UK found that two-thirds of people who were vaccine-hesitant during the ...

While Moderna’s full-year sales landed in the upper end of its target range, Jefferies analysts said further reductions are ...